{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T12:35:52Z","timestamp":1723120552591},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T00:00:00Z","timestamp":1568160000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T00:00:00Z","timestamp":1568160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00105-019-04469-2","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T09:02:36Z","timestamp":1568192556000},"page":"815-830","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Kutane Lymphome"],"prefix":"10.1007","volume":"70","author":[{"given":"Marion","family":"Wobser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Goebeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,11]]},"reference":[{"issue":"20","key":"4469_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow\u00a0SH, Campo\u00a0E, Pileri\u00a0SA, Harris\u00a0NL, Stein\u00a0H, Siebert\u00a0R et\u00a0al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390","journal-title":"Blood"},{"issue":"12","key":"4469_CR2","first-page":"1266","volume":"15","author":"E Dippel","year":"2017","unstructured":"Dippel\u00a0E, Assaf\u00a0C, Becker\u00a0JC, von Bergwelt-Baildon\u00a0M, Beyer\u00a0M, Cozzio\u00a0A et al (2017) S2k guidelines\u2014Cutaneous lymphomas update 2016\u2014Part 1: Classification and diagnosis (ICD10 C82\u2013C86). J\u00a0Dtsch Dermatol Ges 15(12):1266\u20131273","journal-title":"J Dtsch Dermatol Ges"},{"issue":"9","key":"4469_CR3","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s00105-017-4021-5","volume":"68","author":"JP Nicolay","year":"2017","unstructured":"Nicolay\u00a0JP, Assaf\u00a0C (2017) Treatment of mycosis fungoides and S\u00e9zary syndrome. Hautarzt 68(9):702\u2013710","journal-title":"Hautarzt"},{"issue":"4","key":"4469_CR4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/DAD.0b013e31819f19bb","volume":"31","author":"H Beltraminelli","year":"2009","unstructured":"Beltraminelli\u00a0H, Leinweber\u00a0B, Kerl\u00a0H, Cerroni\u00a0L (2009) Primary cutaneous CD4+ small-\/medium-sized pleomorphic T\u2011cell lymphoma: A cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases. Am J Dermatopathol 31(4):317\u2013322","journal-title":"Am J Dermatopathol"},{"issue":"11","key":"4469_CR5","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/cup.12213","volume":"40","author":"M Wobser","year":"2013","unstructured":"Wobser\u00a0M, Petrella\u00a0T, Kneitz\u00a0H, Kerstan\u00a0A, Goebeler\u00a0M, Rosenwald\u00a0A et al (2013) Extrafacial indolent CD8-positive cutaneous lymphoid proliferation with unusual symmetrical presentation involving both feet. J\u00a0Cutan Pathol 40(11):955\u2013961","journal-title":"J Cutan Pathol"},{"issue":"6","key":"4469_CR6","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1111\/bjd.13628","volume":"172","author":"M Wobser","year":"2015","unstructured":"Wobser\u00a0M, Roth\u00a0S, Reinartz\u00a0T, Rosenwald\u00a0A, Goebeler\u00a0M, Geissinger\u00a0E (2015) CD68 expression is a discriminative feature of indolent cutaneous CD8-positive lymphoid proliferation and distinguishes this lymphoma subtype from other CD8-positive cutaneous lymphomas. Br J Dermatol 172(6):1573\u20131580","journal-title":"Br J Dermatol"},{"issue":"6","key":"4469_CR7","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1182\/blood-2002-07-1960","volume":"102","author":"MW Bekkenk","year":"2003","unstructured":"Bekkenk\u00a0MW, Vermeer\u00a0MH, Jansen\u00a0PM, van Marion\u00a0AMW, Canninga-van Dijk\u00a0MR, Kluin\u00a0PM et al (2003) Peripheral T\u2011cell lymphomas unspecified presenting in the skin: Analysis of prognostic factors in a group of 82 patients. Blood 102(6):2213\u20132219","journal-title":"Blood"},{"issue":"1","key":"4469_CR8","first-page":"112","volume":"16","author":"E Dippel","year":"2018","unstructured":"Dippel\u00a0E, Assaf\u00a0C, Becker\u00a0JC, von Bergwelt-Baildon\u00a0M, Beyer\u00a0M, Cozzio\u00a0A et al (2018) S2k guidelines\u2014Cutaneous lymphomas update 2016\u2014Part 2: Treatment and follow-up (ICD10 C82\u2013C86). J\u00a0Dtsch Dermatol Ges 16(1):112\u2013122","journal-title":"J Dtsch Dermatol Ges"},{"issue":"9","key":"4469_CR9","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/s00105-017-4023-3","volume":"68","author":"R Stranzenbach","year":"2017","unstructured":"Stranzenbach\u00a0R, Theurich\u00a0S, Schlaak\u00a0M (2017) Role of stem cell transplantation in treatment of primary cutaneous T\u2011cell lymphoma. Hautarzt 68(9):716\u2013720","journal-title":"Hautarzt"},{"issue":"1","key":"4469_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","volume":"125","author":"CFM Hughes","year":"2015","unstructured":"Hughes\u00a0CFM, Khot\u00a0A, McCormack\u00a0C, Lade\u00a0S, Westerman\u00a0DA, Twigger\u00a0R et\u00a0al (2015) Lack of durable disease control with chemotherapy for mycosis fungoides and S\u00e9zary syndrome: A comparative study of systemic therapy. Blood 125(1):71\u201381","journal-title":"Blood"},{"issue":"8","key":"4469_CR11","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.ctrv.2014.06.005","volume":"40","author":"D Humme","year":"2014","unstructured":"Humme\u00a0D, Nast\u00a0A, Erdmann\u00a0R, Vandersee\u00a0S, Beyer\u00a0M (2014) Systematic review of combination therapies for mycosis fungoides. Cancer Treat Rev 40(8):927\u2013933","journal-title":"Cancer Treat Rev"},{"key":"4469_CR12","first-page":"CD008946","volume":"9","author":"T Weberschock","year":"2012","unstructured":"Weberschock\u00a0T, Strametz\u00a0R, Lorenz\u00a0M, R\u00f6llig\u00a0C, Bunch\u00a0C, Bauer\u00a0A et\u00a0al (2012) Interventions for mycosis fungoides. Cochrane Database Syst Rev 9:CD8946","journal-title":"Cochrane Database Syst Rev"},{"key":"4469_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ctrv.2017.10.007","volume":"61","author":"L Argnani","year":"2017","unstructured":"Argnani\u00a0L, Broccoli\u00a0A, Zinzani\u00a0PL (2017) Cutaneous T\u2011cell lymphomas: Focusing on novel agents in relapsed and refractory disease. Cancer Treat Rev 61:61\u201369","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"4469_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.4103\/ijd.IJD_73_17","volume":"62","author":"M Bagot","year":"2017","unstructured":"Bagot\u00a0M (2017) New targeted treatments for cutaneous T\u2011cell lymphomas. Indian J Dermatol 62(2):142\u2013145","journal-title":"Indian J Dermatol"},{"issue":"32","key":"4469_CR15","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","volume":"33","author":"M Duvic","year":"2015","unstructured":"Duvic\u00a0M, Tetzlaff\u00a0MT, Gangar\u00a0P, Clos\u00a0AL, Sui\u00a0D, Talpur\u00a0R (2015) Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T\u2011cell lymphoma and lymphomatoid papulosis. J\u00a0Clin Oncol 33(32):3759\u20133765","journal-title":"J Clin Oncol"},{"issue":"32","key":"4469_CR16","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","volume":"33","author":"YH Kim","year":"2015","unstructured":"Kim\u00a0YH, Tavallaee\u00a0M, Sundram\u00a0U, Salva\u00a0KA, Wood\u00a0GS, Li\u00a0S et al (2015) Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: A multi-institution collaborative project. J\u00a0Clin Oncol 33(32):3750\u20133758","journal-title":"J Clin Oncol"},{"issue":"10094","key":"4469_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","volume":"390","author":"HM Prince","year":"2017","unstructured":"Prince\u00a0HM, Kim\u00a0YH, Horwitz\u00a0SM, Dummer\u00a0R, Scarisbrick\u00a0J, Quaglino\u00a0P et al (2017) Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T\u2011cell lymphoma (ALCANZA): An international, open-label, randomised, phase 3, multicentre trial. Lancet 390(10094):555\u2013566","journal-title":"Lancet"},{"issue":"12","key":"4469_CR18","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1182\/blood-2015-02-625251","volume":"125","author":"RA Wilcox","year":"2015","unstructured":"Wilcox\u00a0RA (2015) Mogamulizumab: 2 birds, 1 stone. Blood 125(12):1847\u20131848","journal-title":"Blood"},{"issue":"21","key":"4469_CR19","doi-asserted-by":"publisher","first-page":"6494","DOI":"10.1158\/1078-0432.CCR-07-1324","volume":"13","author":"H Yano","year":"2007","unstructured":"Yano\u00a0H, Ishida\u00a0T, Inagaki\u00a0A, Ishii\u00a0T, Ding\u00a0J, Kusumoto\u00a0S et\u00a0al (2007) Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: A novel immunotherapy for aggressive\/refractory Mycosis fungoides and Sezary syndrome. Clin Cancer Res 13(21):6494\u20136500","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4469_CR20","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","volume":"125","author":"M Duvic","year":"2015","unstructured":"Duvic\u00a0M, Pinter-Brown\u00a0LC, Foss\u00a0FM, Sokol\u00a0L, Jorgensen\u00a0JL, Challagundla\u00a0P et al (2015) Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T\u2011cell lymphoma. Blood 125(12):1883\u20131889","journal-title":"Blood"},{"issue":"8","key":"4469_CR21","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1182\/blood-2013-09-525915","volume":"123","author":"C Querfeld","year":"2014","unstructured":"Querfeld\u00a0C, Rosen\u00a0ST, Guitart\u00a0J, Duvic\u00a0M, Kim\u00a0YH, Dusza\u00a0SW et al (2014) Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and S\u00e9zary syndrome. Blood 123(8):1159\u20131166","journal-title":"Blood"},{"issue":"23","key":"4469_CR22","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","volume":"34","author":"AM Lesokhin","year":"2016","unstructured":"Lesokhin\u00a0AM, Ansell\u00a0SM, Armand\u00a0P, Scott\u00a0EC, Halwani\u00a0A, Gutierrez\u00a0M et\u00a0al (2016) Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase Ib study. J\u00a0Clin Oncol 34(23):2698\u20132704","journal-title":"J Clin Oncol"},{"issue":"12","key":"4469_CR23","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/archdermatol.2012.2089","volume":"148","author":"F Cetin\u00f6zman","year":"2012","unstructured":"Cetin\u00f6zman\u00a0F, Jansen\u00a0PM, Vermeer\u00a0MH, Willemze\u00a0R (2012) Differential expression of programmed death\u20111 (PD-1) in S\u00e9zary syndrome and mycosis fungoides. Arch Dermatol 148(12):1379\u20131385","journal-title":"Arch Dermatol"},{"issue":"3","key":"4469_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.it.2017.12.005","volume":"39","author":"A Veillette","year":"2018","unstructured":"Veillette\u00a0A, Chen\u00a0J (2018) SIRP\u03b1-CD47 immune checkpoint blockade in anticancer therapy. Trends Immunol 39(3):173\u2013184. \n                    https:\/\/doi.org\/10.1016\/j.it.2017.12.005","journal-title":"Trends Immunol"},{"issue":"1","key":"4469_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/ajh.24233","volume":"91","author":"RA Wilcox","year":"2016","unstructured":"Wilcox\u00a0RA (2016) Cutaneous T\u2011cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 91(1):151\u2013165","journal-title":"Am J Hematol"},{"issue":"2","key":"4469_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.blre.2015.08.003","volume":"30","author":"J Iqbal","year":"2016","unstructured":"Iqbal\u00a0J, Wilcox\u00a0R, Naushad\u00a0H, Rohr\u00a0J, Heavican\u00a0TB, Wang\u00a0C et al (2016) Genomic signatures in T\u2011cell lymphoma: How can these improve precision in diagnosis and inform prognosis? Blood Rev 30(2):89\u2013100. \n                    https:\/\/doi.org\/10.1016\/j.blre.2015.08.003","journal-title":"Blood Rev"},{"issue":"9","key":"4469_CR27","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/ng.3370","volume":"47","author":"A Ungewickell","year":"2015","unstructured":"Ungewickell\u00a0A, Bhaduri\u00a0A, Rios\u00a0E, Reuter\u00a0J, Lee\u00a0CS, Mah\u00a0A et\u00a0al (2015) Genomic analysis of mycosis fungoides and S\u00e9zary syndrome identifies recurrent alterations in TNFR2. Nat Genet 47(9):1056\u20131060","journal-title":"Nat Genet"},{"issue":"4","key":"4469_CR28","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1182\/blood-2014-11-611194","volume":"126","author":"LY McGirt","year":"2015","unstructured":"McGirt\u00a0LY, Jia\u00a0P, Baerenwald\u00a0DA, Duszynski\u00a0RJ, Dahlman\u00a0KB, Zic\u00a0JA et al (2015) Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood 126(4):508\u2013519","journal-title":"Blood"},{"issue":"12","key":"4469_CR29","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/ng.3444","volume":"47","author":"L Wang","year":"2015","unstructured":"Wang\u00a0L, Ni\u00a0X, Covington\u00a0KR, Yang\u00a0BY, Shiu\u00a0J, Zhang\u00a0X et\u00a0al (2015) Genomic profiling of S\u00e9zary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet 47(12):1426\u20131434","journal-title":"Nat Genet"},{"issue":"6","key":"4469_CR30","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1182\/blood-2016-01-694117","volume":"128","author":"JP Nicolay","year":"2016","unstructured":"Nicolay\u00a0JP, M\u00fcller-Decker\u00a0K, Schroeder\u00a0A, Brechmann\u00a0M, M\u00f6bs\u00a0M, G\u00e9raud\u00a0C et al (2016) Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-\u03baB. Blood 128(6):805\u2013815","journal-title":"Blood"},{"issue":"13","key":"4469_CR31","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1158\/1078-0432.CCR-11-3144","volume":"18","author":"HM Prince","year":"2012","unstructured":"Prince\u00a0HM, Dickinson\u00a0M (2012) Romidepsin for cutaneous T\u2011cell lymphoma. Clin Cancer Res 18(13):3509\u20133515","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4469_CR32","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/2040620715592567","volume":"6","author":"A Sawas","year":"2015","unstructured":"Sawas\u00a0A, Radeski\u00a0D, O\u2019Connor\u00a0OA (2015) Belinostat in patients with refractory or relapsed peripheral T\u2011cell lymphoma: A perspective review. Ther Adv Hematol 6(4):202\u2013208","journal-title":"Ther Adv Hematol"},{"issue":"13","key":"4469_CR33","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1182\/blood-2013-05-504308","volume":"123","author":"JP Vaqu\u00e9","year":"2014","unstructured":"Vaqu\u00e9\u00a0JP, G\u00f3mez-L\u00f3pez\u00a0G, Mons\u00e1lvez\u00a0V, Varela\u00a0I, Mart\u00ednez\u00a0N, P\u00e9rez\u00a0C et al (2014) PLCG1 mutations in cutaneous T\u2011cell lymphomas. Blood 123(13):2034\u20132043","journal-title":"Blood"},{"issue":"9","key":"4469_CR34","first-page":"906","volume":"5","author":"E Rallis","year":"2006","unstructured":"Rallis\u00a0E, Economidi\u00a0A, Verros\u00a0C, Papadakis\u00a0P (2006) Successful treatment of patch type mycosis fungoides with tacrolimus ointment 0.1%. J\u00a0Drugs Dermatol 5(9):906\u2013907","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"4469_CR35","first-page":"148","volume":"18","author":"MC Mart\u00ednez-Gonz\u00e1lez","year":"2008","unstructured":"Mart\u00ednez-Gonz\u00e1lez\u00a0MC, Verea-Hernando\u00a0MM, Yebra-Pimentel\u00a0MT, Del Pozo\u00a0J, Mazaira\u00a0M, Fonseca\u00a0E (2008) Imiquimod in mycosis fungoides. Eur J Dermatol 18(2):148\u2013152","journal-title":"Eur J Dermatol"},{"issue":"12","key":"4469_CR36","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1182\/blood-2015-02-630335","volume":"126","author":"AH Rook","year":"2015","unstructured":"Rook\u00a0AH, Gelfand\u00a0JC, Wysocka\u00a0M, Troxel\u00a0AB, Benoit\u00a0B, Surber\u00a0C et al (2015) Topical resiquimod can induce disease regression and enhance T\u2011cell effector functions in cutaneous T\u2011cell lymphoma. Blood 126(12):1452\u20131461","journal-title":"Blood"},{"issue":"1","key":"4469_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","volume":"149","author":"SR Lessin","year":"2013","unstructured":"Lessin\u00a0SR, Duvic\u00a0M, Guitart\u00a0J, Pandya\u00a0AG, Strober\u00a0BE, Olsen\u00a0EA et al (2013) Topical chemotherapy in cutaneous T\u2011cell lymphoma: Positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02\u202f%, gel in mycosis fungoides. JAMA Dermatol 149(1):25\u201332","journal-title":"JAMA Dermatol"},{"issue":"11","key":"4469_CR38","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1001\/archderm.1996.03890350051009","volume":"132","author":"YH Kim","year":"1996","unstructured":"Kim\u00a0YH, Jensen\u00a0RA, Watanabe\u00a0GL, Varghese\u00a0A, Hoppe\u00a0RT (1996) Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 132(11):1309\u20131313","journal-title":"Arch Dermatol"},{"issue":"7","key":"4469_CR39","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.jid.2018.02.015","volume":"138","author":"K Maurus","year":"2018","unstructured":"Maurus\u00a0K, Appenzeller\u00a0S, Roth\u00a0S, Kuper\u00a0J, Rost\u00a0S, Meierjohann\u00a0S et\u00a0al (2018) Panel sequencing shows recurrent genetic FAS alterations in primary cutaneous marginal zone lymphoma. J\u00a0Invest Dermatol 138(7):1573\u20131581","journal-title":"J Invest Dermatol"},{"issue":"9","key":"4469_CR40","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00105-017-4022-4","volume":"68","author":"M Wobser","year":"2017","unstructured":"Wobser\u00a0M (2017) Treatment of indolent cutaneous B\u2011cell lymphoma. Hautarzt 68(9):721\u2013726","journal-title":"Hautarzt"},{"issue":"9","key":"4469_CR41","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00105-017-4018-0","volume":"68","author":"C Lamos","year":"2017","unstructured":"Lamos\u00a0C, Dippel\u00a0E (2017) Aggressive primary cutaneous B\u2011cell lymphomas and novel EBV+ entities. Hautarzt 68(9):727\u2013739","journal-title":"Hautarzt"},{"issue":"12","key":"4469_CR42","first-page":"1207","volume":"14","author":"JP Nicolay","year":"2016","unstructured":"Nicolay\u00a0JP, Wobser\u00a0M (2016) B\u2011Zell-Lymphome der Haut \u2013 Pathogenese, Diagnostik und Therapie. J\u00a0Dtsch Dermatol Ges 14(12):1207\u20131225","journal-title":"J Dtsch Dermatol Ges"},{"issue":"7","key":"4469_CR43","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1182\/blood-2005-03-1175","volume":"106","author":"K Kodama","year":"2005","unstructured":"Kodama\u00a0K, Massone\u00a0C, Chott\u00a0A, Metze\u00a0D, Kerl\u00a0H, Cerroni\u00a0L (2005) Primary cutaneous large B\u2011cell lymphomas: Clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood 106(7):2491\u20132497","journal-title":"Blood"},{"issue":"12","key":"4469_CR44","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1200\/JCO.2006.09.6396","volume":"25","author":"NJ Senff","year":"2007","unstructured":"Senff\u00a0NJ, Hoefnagel\u00a0JJ, Jansen\u00a0PM, Vermeer\u00a0MH, van Baarlen\u00a0J, Blokx\u00a0WA et al (2007) Reclassification of 300 primary cutaneous B\u2011Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: Comparison with previous classifications and identification of prognostic markers. J\u00a0Clin Oncol 25(12):1581\u20131587","journal-title":"J Clin Oncol"},{"issue":"16","key":"4469_CR45","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1200\/JCO.2001.19.16.3602","volume":"19","author":"F Grange","year":"2001","unstructured":"Grange\u00a0F, Bekkenk\u00a0MW, Wechsler\u00a0J, Meijer\u00a0CJ, Cerroni\u00a0L, Bernengo\u00a0M et al (2001) Prognostic factors in primary cutaneous large B\u2011cell lymphomas: A European multicenter study. J\u00a0Clin Oncol 19(16):3602\u20133610","journal-title":"J Clin Oncol"},{"issue":"5","key":"4469_CR46","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1001\/jamadermatol.2013.7452","volume":"150","author":"F Grange","year":"2014","unstructured":"Grange\u00a0F, Joly\u00a0P, Barbe\u00a0C, Bagot\u00a0M, Dalle\u00a0S, Ingen-Housz-Oro\u00a0S et al (2014) Improvement of survival in patients with primary cutaneous diffuse large B\u2011cell lymphoma, leg type, in France. JAMA Dermatol 150(5):535\u2013541","journal-title":"JAMA Dermatol"},{"issue":"1","key":"4469_CR47","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1182\/blood-2015-03-634394","volume":"127","author":"JC Byrd","year":"2016","unstructured":"Byrd\u00a0JC, Flynn\u00a0JM, Kipps\u00a0TJ, Boxer\u00a0M, Kolibaba\u00a0KS, Carlile\u00a0DJ et\u00a0al (2016) Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood 127(1):79\u201386","journal-title":"Blood"},{"key":"4469_CR48","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1749-6632.2012.06661.x","volume":"1263","author":"IV Gupta","year":"2012","unstructured":"Gupta\u00a0IV, Jewell\u00a0RC (2012) Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies. Ann N Y Acad Sci 1263:43\u201356","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"4469_CR49","first-page":"10705","volume":"8","author":"C Fang","year":"2015","unstructured":"Fang\u00a0C, Zhu\u00a0D, Dong\u00a0H, Ji\u00a0M, Wu\u00a0J, Xu\u00a0X et al (2015) Lenalidomide alone or in combination with chemotherapy treatment for subtypes of diffuse large B cell lymphoma: A\u00a0systematic review and meta-analysis. Int J Clin Exp Med 8(7):10705\u201310713","journal-title":"Int J Clin Exp Med"},{"issue":"6","key":"4469_CR50","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/ejh.12768","volume":"97","author":"PL Zinzani","year":"2016","unstructured":"Zinzani\u00a0PL, Corradini\u00a0P, Martelli\u00a0M, Minotti\u00a0G, Oliva\u00a0S, Spina\u00a0M et al (2016) Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: A SIE, SIES, and GITMO consensus paper. Eur J Haematol 97(6):554\u2013561","journal-title":"Eur J Haematol"},{"issue":"2","key":"4469_CR51","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/gcc.22126","volume":"53","author":"E Bohers","year":"2014","unstructured":"Bohers\u00a0E, Mareschal\u00a0S, Bouzelfen\u00a0A, Marchand\u00a0V, Ruminy\u00a0P, Maingonnat\u00a0C et al (2014) Targetable activating mutations are very frequent in GCB and ABC diffuse large B\u2011cell lymphoma. Genes Chromosomes Cancer 53(2):144\u2013153","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"4469_CR52","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/modpathol.2013.156","volume":"27","author":"A Pham-Ledard","year":"2014","unstructured":"Pham-Ledard\u00a0A, Prochazkova-Carlotti\u00a0M, Andrique\u00a0L, Cappellen\u00a0D, Vergier\u00a0B, Martinez\u00a0F et al (2014) Multiple genetic alterations in primary cutaneous large B\u2011cell lymphoma, leg type support a common lymphomagenesis with activated B\u2011cell-like diffuse large B\u2011cell lymphoma. Mod Pathol 27(3):402\u2013411","journal-title":"Mod Pathol"},{"issue":"8","key":"4469_CR53","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/j.jid.2016.04.018","volume":"136","author":"S Menguy","year":"2016","unstructured":"Menguy\u00a0S, Gros\u00a0A, Pham-Ledard\u00a0A, Battistella\u00a0M, Ortonne\u00a0N, Comoz\u00a0F et al (2016) MYD88 somatic mutation is a diagnostic criterion in primary cutaneous large B\u2011cell lymphoma. J\u00a0Invest Dermatol 136(8):1741\u20131744. \n                    https:\/\/doi.org\/10.1016\/j.jid.2016.04.018","journal-title":"J Invest Dermatol"},{"issue":"1","key":"4469_CR54","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/jid.2013.265","volume":"134","author":"L Koens","year":"2014","unstructured":"Koens\u00a0L, Zoutman\u00a0WH, Ngarmlertsirichai\u00a0P, Przybylski\u00a0GK, Grabarczyk\u00a0P, Vermeer\u00a0MH et al (2014) Nuclear factor-\u03baB pathway-activating gene aberrancies in primary cutaneous large B\u2011cell lymphoma, leg type. J\u00a0Invest Dermatol 134(1):290\u2013292","journal-title":"J Invest Dermatol"},{"issue":"9","key":"4469_CR55","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/j.jid.2017.04.010","volume":"137","author":"S Mareschal","year":"2017","unstructured":"Mareschal\u00a0S, Pham-Ledard\u00a0A, Viailly\u00a0PJ, Dubois\u00a0S, Bertrand\u00a0P, Maingonnat\u00a0C et al (2017) Identification of somatic mutations in primary cutaneous diffuse large B\u2011cell lymphoma, leg type by massive parallel sequencing. J\u00a0Invest Dermatol 137(9):1984\u20131994","journal-title":"J Invest Dermatol"},{"issue":"97","key":"4469_CR56","first-page":"51","volume":"18","author":"F Jardin","year":"2014","unstructured":"Jardin\u00a0F (2014) Next generation sequencing and the management of diffuse large B\u2011cell lymphoma: From whole exome analysis to targeted therapy. Discov Med 18(97):51\u201365","journal-title":"Discov Med"},{"issue":"1","key":"4469_CR57","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","volume":"125","author":"LH Sehn","year":"2015","unstructured":"Sehn\u00a0LH, Gascoyne\u00a0RD (2015) Diffuse large B\u2011cell lymphoma: Optimizing outcome in the context of clinical and biologic heterogeneity. Blood 125(1):22\u201332","journal-title":"Blood"},{"issue":"4","key":"4469_CR58","doi-asserted-by":"publisher","first-page":"6067","DOI":"10.4081\/rt.2015.6067","volume":"7","author":"E Gupta","year":"2015","unstructured":"Gupta\u00a0E, Accurso\u00a0J, Sluzevich\u00a0J, Menke\u00a0DM, Tun\u00a0HW (2015) Excellent outcome of immunomodulation or Bruton\u2019s tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B\u2011cell lymphoma, leg type. Rare Tumors 7(4):6067","journal-title":"Rare Tumors"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-019-04469-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-019-04469-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-019-04469-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T19:07:28Z","timestamp":1599764848000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-019-04469-2"}},"subtitle":["Klinik \u2013 Diagnostik \u2013 Therapie"],"short-title":[],"issued":{"date-parts":[[2019,9,11]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["4469"],"URL":"https:\/\/doi.org\/10.1007\/s00105-019-04469-2","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,11]]},"assertion":[{"value":"11 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt."}},{"value":"<b>M. Wobser<\/b>: A. Finanzielle Interessen: Themenbezogene Forschungsf\u00f6rderung durch: IZKF und Comprehensive Cancer Center W\u00fcrzburg, Deutsche Stiftung Dermatologie, 4SC AG. \u2013 Kostenerstattung von themenbezogenen Fortbildungsveranstaltungen durch: Arbeitsgemeinschaft Dermatologische Histologie, Arbeitsgemeinschaft Dermatologische Onkologie, Deutsche Dermatologische Gesellschaft, European Organisation of Research and Treatment of Cancer (EORTC) and International Society of Cutaneous Lymphomas (ISCL) | Themenbezogene Referentenhonorar durch: Takeda, Mallinckrodt, Kyowa | Themenbezogenes Sponsoring von Fortbildungsveranstaltungen durch: Takeda, Mallinckrodt, Kyowa, 4SC AG, Bristol-Myers-Squibb, Recordati Rare Diseases (jeweils Vertrag mit dem Universit\u00e4tsklinkum W\u00fcrzburg). \u2013 Berater von: Takeda, Mallinckrodt, Kyowa. \u2013 Keine themenbezogenen Patienten\/Gesch\u00e4ftsanteile\/Aktien o.\u00e4. \u2013 B. Nichtfinanzielle Interessen: Ober\u00e4rztin der Universit\u00e4tshautklinik W\u00fcrzburg, Leitung Arbeitsgruppe Kutane Lymphome der Universit\u00e4tshautklinik W\u00fcrzburg und stellvertretende Leitung Dermatohistologie | Mitgliedschaften: Arbeitsgemeinschaft Dermatologische Onkologie (ADO), Deutsche Krebsgesellschaft (DKG), Arbeitsgemeinschaft Experimentelle Krebsforschung (AEK), Deutsche Dermatologische Gesellschaft (DDG), Arbeitsgemeinschaft P\u00e4diatrische Dermatologie (APD), Arbeitsgemeinschaft Dermatologische Histologie (ADH), International Society of Cutaneous Lymphomas (ISCL), European Organization for Research and Treatment of Cancer (EORTC), Leitlinienkommission Kutane Lymphome der DDG\/ADO. <b>M.\u00a0Goebeler<\/b>: A. Finanzielle Interessen: Keine themenbezogene Forschungsf\u00f6rderung. \u2013 Keine themenbezogenen Honorare oder Kostenerstattungen | Anmerkung: Themenbezogene Fortbildungsveranstaltungen der von mir geleiteten Klinik f\u00fcr Dermatologie, Venerologie und Allergologie wurden von folgenden Firmen im Sinne des Sponsoring (jeweils Vertrag mit dem Univ.-Klinikum W\u00fcrzburg) unterst\u00fctzt: Mallinckroodt Pharmaceuticals, Takeda Pharma, 4SC AG, Bristol Myers Squibb. \u2013 Keine themenbezogenen Honorare als Referent, Berater o.\u00e4. \u2013 Keine themenbezogenen Patente\/Gesch\u00e4ftsanteile oder Aktien o.\u00e4. \u2013 B. Nichtfinanzielle Interessen: Univ.-Prof. und Direktor der Klinik f\u00fcr Dermatologie, Venerologie und Allergologie, Universitatsklinikum W\u00fcrzburg (beamtet) | Prodekan der Med. Fakult\u00e4t der Univ. W\u00fcrzburg | Mitglied in folgenden Fachgesellschaften: DDG, ADF, ESDR, WDG, Gesellschaft f\u00fcr Immunologie, Deutscher Hochschulverband | Vorstandsmitglied der Dt. Dermatol. Gesellschaft, Vorsitzender der W\u00fcrzburger Dermatologischen Gesellschaft.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren."}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung."}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}